Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Mar 31, 2006
Notice of Annual General Meeting
Mar 31, 2006
Annual Report
Mar 22, 2006
Preclinical results for oral administration of NNZ-2566
Mar 06, 2006
NNZ-2566 Phase 1 trial to commence
Feb 28, 2006
Preliminary Final Report
Feb 07, 2006
Investor Update February 2006
Feb 01, 2006
FDA pre-clinical requirements to Phase 3 completed
Jan 31, 2006
Commitments Test Entity - Fourth Quarter Report
Jan 25, 2006
Appendix 3B End of Restriction Period
Previous
1
2
3
4
5